API

Aop: 61

AOP Title

?


NFE2L2/FXR activation leading to hepatic steatosis

Short name:

?

NRF2/FXR to steatosis

Authors

?


Michelle Angrish, Brian Chorley, U.S. EPA

Point of Contact

?


Michelle Angrish

Contributors

?


  • Brian Chorley
  • Michelle Angrish
  • Lyle Burgoon

Status

?

Author status OECD status OECD project SAAOP status
Under development: Not open for comment. Do not cite Under Development 1.29 Included in OECD Work Plan


This AOP was last modified on February 26, 2017 20:12

?

Revision dates for related pages

Page Revision Date/Time
Activation, NRF2 September 16, 2017 10:15
Activation, NR1H4 September 16, 2017 10:15
Activation, SHP September 16, 2017 10:15
Activation, PPARα September 16, 2017 10:14
Decreased, DHB4/HSD17B4 September 16, 2017 10:15
Inhibition, Mitochondrial fatty acid beta-oxidation September 16, 2017 10:15
Activation, LXR alpha September 16, 2017 10:15
Increased, Liver Steatosis September 16, 2017 10:14
Inhibition, SREBP1c September 16, 2017 10:15
Activation, MTTP September 16, 2017 10:15
Increased, ApoB100 September 16, 2017 10:15
Increased, Triglyceride September 16, 2017 10:15
Increased, De Novo FA synthesis September 16, 2017 10:15
Activation, NRF2 leads to Activation, NR1H4 December 03, 2016 16:37
Activation, NR1H4 leads to Activation, SHP December 03, 2016 16:37
Activation, NR1H4 leads to Activation, PPARα December 03, 2016 16:37
Activation, PPARα leads to Activation, LXR alpha December 03, 2016 16:37
Decreased, DHB4/HSD17B4 leads to Inhibition, Mitochondrial fatty acid beta-oxidation December 03, 2016 16:37
Inhibition, Mitochondrial fatty acid beta-oxidation leads to Increased, Liver Steatosis December 03, 2016 16:37
Activation, SHP leads to Inhibition, SREBP1c December 03, 2016 16:38
Activation, LXR alpha leads to Increased, De Novo FA synthesis July 18, 2017 16:56
Increased, De Novo FA synthesis leads to Increased, Liver Steatosis July 18, 2017 16:57

Abstract

?



Background (optional)

?



Summary of the AOP

?



Stressors

?


Molecular Initiating Event

?

Title Short name
Activation, NRF2 Activation, NRF2
Activation, NR1H4 Activation, NR1H4

Key Events

?

Title Short name
Activation, SHP Activation, SHP
Activation, PPARα Activation, PPARα
Decreased, DHB4/HSD17B4 Decreased, DHB4/HSD17B4
Inhibition, Mitochondrial fatty acid beta-oxidation Inhibition, Mitochondrial fatty acid beta-oxidation
Activation, LXR alpha Activation, LXR alpha
Inhibition, SREBP1c Inhibition, SREBP1c
Activation, MTTP Activation, MTTP
Increased, ApoB100 Increased, ApoB100
Increased, Triglyceride Increased, Triglyceride
Increased, De Novo FA synthesis Increased, De Novo FA synthesis

Adverse Outcome

?

Title Short name
Increased, Liver Steatosis Increased, Liver Steatosis

Relationships Between Two Key Events (Including MIEs and AOs)

?

Network View

?

 

Life Stage Applicability

?


Taxonomic Applicability

?


Sex Applicability

?


Graphical Representation

?

Click to download graphical representation template

Overall Assessment of the AOP

?



Domain of Applicability

?


Essentiality of the Key Events

?


Weight of Evidence Summary

?


Quantitative Considerations

?


Considerations for Potential Applications of the AOP (optional)

?



References

?